Single-dose LSD drug successfully treats depression in key human trial

Definium Therapeutics has made a significant breakthrough in mental health treatment by reporting successful results from a phase 3 trial of their LSD-based drug, DT120, for major depressive disorder. This marks the first trial of its kind, achieving its primary goal and all secondary efficacy endpoints. The implications are huge, as traditional antidepressants often have a delayed onset and come with side effects, whereas this single-dose treatment could offer quicker relief. This could revolutionize how we approach depression treatment, potentially offering a more effective and immediate solution.